Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
Abstract
The B-cell CD20 antigen is one of the most reliable surface targets in immunotherapy of B lymphoma. In this project, we studied the production and characterization of a new monoclonal antibody against chimeric human CD20 extra loops (hCD20 exl). The results showed that clone C12H, IgG2/k isotype reacted with the antigen in ELISA and immunoblot. The Kd value was found to be 2×10-9M and flow cytometry results showed that 99.9% and 99.7% of the Daudi and Raji cells respectively were stained with C12H monoclonal antibody (mab) but not with Jurkat cell lines. It also effectively competed with Rituximab, thus, the staining of the Daudi and Raji cell lines was reduced to 55.9% and 40.5% of cells respectively. Based on the high affinity reaction of C12H mab and appropriate reactivity of C12H mab with the native antigen on the surface of Raji and Daudi cells in flow cytometry, it was concluded that development and evaluation of C12H mab could be a beneficial candidate for further application in genetically engineered monoclonal antibody.
1. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol. 2013; 131(4):959-71.
2. Van der Kolk L, Evers L, Omene C, Lens S, Lederman S, van Lier R, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002; 16(9):1735-44.
3. Gholipour-Shoiili A, Gholipour-Shoiili H, Taheri S.CD20 antigen expression by lymphoma cells in lung allograft recipients is associated with higher remission rate and superior survival: A study on heart and lung transplant recipients. Saudi J Kidney Dis Transpl 2014;25(1):29-37.
4. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ.CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47(2):107-14.
5. Sathiya M, Muthuchelian K. Significance of Immunologic Markers in the Diagnosis of Lymphoma. Academic Journal of Cancer Research 2009; 2(1):40-50.
6. Pescovitz MD. Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action. Am J Transplant 2006; 6( 5 pt 1):859-66.
7. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, et al.Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 2014; 93(4):541-56.
8. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55(2):188-96.
9. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2(6):676-90.
10. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013;27(5):495-507.
11. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186(6):3762-9.
12. Deligne C, Metidji A, Fridman WH, Teillaud JL. Anti- CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 2014;18(10):275.
13. Fasihi-Ramandi M, Nejad-Moghaddam A, Arabsalmany F, Asgari S, Ahmadi-Renani S, Ahmadi K. Production and characterization of monoclonal antibody against recombinant outer membrane protein. Am J Immunol 2014; 10(1):56-62.
14. Galfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 1980; 73( Pt B ):3-46.
15. Sharifzadeh S, Modjtahedi H, Jedi Tehrani M, Bayat A, Ghaderi A. Production and characterization of a monoclonal antibody against an antigen on the surface of non-small cell carcinoma of the lung. Iran J Immunol 2007; 4(4):206-14.
16. Brodeur B, Tsang P, Larose Y. Parameters affecting ascites tumour formation in mice and monoclonal antibody production. J Immunol Methods 1984;71(2):265-72.
17. Majidi J, Zavaran Hosseini A, Hassan ZM, Alimohamadian MH. Production of monoclonal antibody against human immunoglobulin. Iran J.Allergy Asthma immunol 2000; 1(2): 81-87.
18. Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987; 100(1-2):173-9.
19. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012; 5(1):64.
20. Habibi Anbouhi M, Feiz Barazandeh A, Bouzari S, Abolhassani M, Khanahmad H, Golkar M, et al. Functional Recombinant Extra Membrane Loop of Human CD20, an Alternative of the Full Length CD20 Antigen. Iran Biomed J 2012; 16(3):121-1.
21. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al.Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res 2004; 10(8):2868-78.
22. Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34(1):74-9.
23. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011; 24(2):203-16.
24.Zhang X, Sun Z, Yu W, Cheng JZ. [Cloning and expression of fusion gene of transmembrane domain of human CD20 and g3pN in Escherichia coli]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004; 20(4):481-3.
25. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118(2):358-67.
26. Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006; 33(2 Suppl 5):S2-14.
27. Sitaru C, Thiel J. The need for markers and predictors of Rituximab treatment resistance. Exp Dermatol 2014;23(4):236-7.
28. Gagez AL, Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 2014;26(5):484-91.
29. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12(10):2031-42.
30. Deans JP, Li H, Polyak MJ. CD20‐mediated apoptosis:signalling through lipid rafts. Immunology 2002;107(2):176-82.
31. Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2012; 5(1):22-33.
| Files | ||
| Issue | Vol 14, No 5 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| CD20 Immunotherapy Lymphoma Monoclonal antibody | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
